赛隆药业集团股份有限公司 2025年半年度业绩预告

Group 1 - The company expects a net profit to be negative for the period from January 1, 2025, to June 30, 2025 [1] - The main reason for the expected loss is the intensified market competition due to the ongoing drug procurement policy, leading to a decrease in drug sales prices and a decline in market demand for certain products [1] - The company's operating revenue and gross margin are expected to decrease compared to the same period last year, contributing to the anticipated operating loss [1] Group 2 - The data related to the performance forecast is based on preliminary calculations by the company's finance department and has not been audited by the accounting firm [1] - The company had reported negative total profit, net profit, and net profit after deducting non-recurring gains and losses for the year 2024, with operating revenue below 300 million [2] - The company's stock was subject to delisting risk warning due to the negative financial results, and if certain conditions are met, the stock may face termination of listing [2]